{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:13:50Z","timestamp":1778825630522,"version":"3.51.4"},"reference-count":23,"publisher":"Wiley","issue":"S60","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":4527,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1996,12]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Drug\u2010induced blood dyscrasias may be due to toxicity of the drug, inborn errors of metabolism or immunological reactions. In the latter case, drug\u2010induced antibodies are directed to specific target cells, such as platelets (thrombocytopenia) or granulocytes (agranulocytosis). Some of these immune mechanisms are based on the physical interaction between drug, antibody and target cells. A particular drug may bind to the surface of the blood cell which, as a carrier of the drug, will be destroyed as part of the immune reaction to the drug (hapten mechanism). Other drugs will form immune complexes with drug\u2010specific antibodies. These immune complexes will bind to certain blood cells and destroy them as innocent bystanders (immune complex mechanism). <jats:italic>In vitro<\/jats:italic> assays are described which enable the offending drug to be detected by mimicking these immune mechanisms using patient serum, platelets or granulocytes, and the suspected drug. The diagnostic value of these <jats:italic>in vitro<\/jats:italic> assays is discussed.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1996.tb01648.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T08:45:32Z","timestamp":1279442732000},"page":"64-68","source":"Crossref","is-referenced-by-count":30,"title":["Immune mechanisms leading to drug\u2010induced blood dyscrasias"],"prefix":"10.1111","volume":"57","author":[{"given":"F. H. J.","family":"Claas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197503062921006"},{"key":"e_1_2_1_3_2","first-page":"303","article-title":"The blood picture in purpura","volume":"13","author":"Rosenthal N","year":"1928","journal-title":"J Lab Clin Med"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1934.02750100021006"},{"key":"e_1_2_1_5_2","first-page":"249","article-title":"The pathogenesis of thrombocytopenic purpura due to hypersensitivity to sedormid","volume":"7","author":"Ackroyd JF","year":"1949","journal-title":"Clin Sci"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000204146"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-60-3-506"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood.V77.10.2190.2190","article-title":"Characterization of the binding domains on platelet glycoproteins 1b\u20101X and IIb\/IIIa for quinine\/quinidine\u2010dependent antibodies","volume":"77","author":"Chong BH","year":"1991","journal-title":"Blood"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1981.tb01055.x"},{"key":"e_1_2_1_10_2","first-page":"338","article-title":"Induction of immune response and the role of antibody specificity in drug\u2010hypersensitivity\u2010type hemolytic anemia and thrombocytopenia","volume":"2","author":"Levine BB","year":"1965","journal-title":"Semin Hematol"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1182\/blood.V82.10.3075.3075","article-title":"Severe thrombocytopenia in an acquired immunodeficiency syndrome patient associated with pentamidine\u2010dependent antibodies specific for glycoprotein IIb\/IIIa","volume":"82","author":"Christie DG","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.11.3232.3232"},{"key":"e_1_2_1_13_2","first-page":"135","article-title":"The interaction of drugs and endogenous substances with HLA class I antigens","volume":"36","author":"Claas FHJ","year":"1985","journal-title":"Prog Allergy"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1977.tb00621.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-2478(81)90027-4"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(66)92423-8","article-title":"Autoimmune haemolytic anaemia associated with a\u2010methyldopa therapy","author":"Worlledge SM","year":"1966","journal-title":"Lancet"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V56.3.388.388"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197208242870803"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198508223130803"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197909203011201"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb04130.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1990.30891020326.x"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V86.3.1177.1177","article-title":"HLA association in clozapine induced agranulocytosis","volume":"86","author":"Yunis J","year":"1995","journal-title":"Blood"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199200071-00004"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1996.tb01648.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1996.tb01648.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:17:32Z","timestamp":1698405452000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1996.tb01648.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,12]]},"references-count":23,"journal-issue":{"issue":"S60","published-print":{"date-parts":[[1996,12]]}},"alternative-id":["10.1111\/j.1600-0609.1996.tb01648.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1996.tb01648.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,12]]}}}